ArticleScientific reports2023
Accurate clinical toxicity prediction using multi-task deep neural nets and contrastive molecular explanations.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Exploring the potential of computer simulation models in drug testing and biomedical research: a systematic review.Frontiers in pharmacology · 2025Pooled it
- AI/ML-based computational models for toxicity prediction.Environmental science and pollution research international · 2026Review
- A Multimodal Generative AI Framework for Predicting the Toxicity of Nanoparticles.Nanomaterials (Basel, Switzerland) · 2026Article
- Unlabeled but Not Unseen: Cytotoxicity Classification of Re(I) Tricarbonyl Complexes via K‑Means Clustering.ACS omega · 2026Article
- Integrating chemical structure and high-throughput transcriptomics for mechanistically interpretable Tox21 bioactivity prediction.Journal of cheminformatics · 2026Article
- "The Dose Makes the Poison": Relevance of Paracelsus's Principle for Modern Chemical Hazard Assessment with New Approach Methodologies.Environmental science & technology · 2026Article
- Machine learning prediction of bile salt export pump inhibition with Boruta feature selection in imbalanced data.Frontiers in pharmacology · 2026Article
- AI-based methods for the assessment of DNA damage and repair mechanisms.Frontiers in systems biology · 2026Review
- Empowering photodynamic therapy with artificial intelligence: current trends and future directions.Frontiers in oncology · 2026Review
- Artificial Intelligence and Machine Learning-Based Approaches for Genetic Damage Prediction.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Multi-task deep learning models for mechanism-based prediction of developmental and reproductive toxicity (DART) using ToxCast bioassays.Frontiers in toxicology · 2026Article
- Network pharmacology and molecular dynamics simulation elucidate the potential mechanism of Batatasin-III in Bletilla striata against ulcerative colitis.Scientific reports · 2025Article
- Identification and Evaluation of Natural Compounds as Potential Inhibitors of NS2B-NS3 Zika Virus Protease: A Computational Approach.Molecular biotechnology · 2025Article
- Enhancing multi-task in vivo toxicity prediction via integrated knowledge transfer of chemical knowledge and in vitro toxicity information.Journal of cheminformatics · 2025Article
- Drug toxicity prediction based on genotype-phenotype differences between preclinical models and humans.EBioMedicine · 2025Article
- Computational toxicology in drug discovery: applications of artificial intelligence in ADMET and toxicity prediction.Briefings in bioinformatics · 2025Review
- Mixture of experts for multitask learning in cardiotoxicity assessment.Journal of cheminformatics · 2025Article
- Property-driven localization and characterization in deep molecular representations.Scientific reports · 2025Article
- ToxACoL: an endpoint-aware and task-focused compound representation learning paradigm for acute toxicity assessment.Nature communications · 2025Article
- Computational drug repurposing: approaches, evaluation of in silico resources and case studies.Nature reviews. Drug discovery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Explainable machine learning for molecular toxicity prediction is a promising approach for efficient drug development and chemical safety. A predictive ML model of toxicity can reduce experimental cost and time while mitigating ethical concerns by significantly reducing animal and clinical testing. Herein, we use a deep learning framework for simultaneously modeling in vitro, in vivo, and clinical toxicity data. Two different molecular input representations are used; Morgan fingerprints and pre-trained SMILES embeddings. A multi-task deep learning model accurately predicts toxicity for all endpoints, including clinical, as indicated by the area under the Receiver Operator Characteristic curve and balanced accuracy. In particular, pre-trained molecular SMILES embeddings as input to the multi-task model improved clinical toxicity predictions compared to existing models in MoleculeNet benchmark. Additionally, our multitask approach is comprehensive in the sense that it is comparable to state-of-the-art approaches for specific endpoints in in vitro, in vivo and clinical platforms. Through both the multi-task model and transfer learning, we were able to indicate the minimal need of in vivo data for clinical toxicity predictions. To provide confidence and explain the model's predictions, we adapt a post-hoc contrastive explanation method that returns pertinent positive and negative features, which correspond well to known mutagenic and reactive toxicophores, such as unsubstituted bonded heteroatoms, aromatic amines, and Michael receptors. Furthermore, toxicophore recovery by pertinent feature analysis captures more of the in vitro (53%) and in vivo (56%), rather than of the clinical (8%), endpoints, and indeed uncovers a preference in known toxicophore data towards in vitro and in vivo experimental data. To our knowledge, this is the first contrastive explanation, using both present and absent substructures, for predictions of clinical and in vivo molecular toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.